Some Healthcare/biotechs on my list for 2025, with many already owned.
OCC - Orthocell -some big gains late in 2024, but outlook looks very promising going into 2025 CC5 - 2025 should see some continued orders of machines that will rerate the stock. I believe it likely Astra orders more but also that a nother one or two pharmas come on board MEM - Low market cap, renewed management and better focus. Reproductive sector with device for humans, horses and cattle. EIQ - traction being gained in heart sector - FDA approval likely in 2025 PCK - 2025 should bring FDA approval, children's app rollout and expansion in the UK. RCE - a stock whose SP has been a dud for a while. But now grants from US DoD and Phase III trials in Indonesia for diabetic foot ulcers. Burns and UTI treatments are still there but on back burner as they try and get to commercial revenue with diabetic foot ulcer treatment. BOT - treatment for profuse weating now on market after FDA approval DXB - Lung health sector - making solid advances PAR - after the mkt gets over the CR hangover, this should rise as it heads towards approvals
I would tip all of these to make in excess of 25% over the next 12 months. I will likely tip them throughout the year and try and pick the 8 week windows where they will do best !
